Abstract
The mammalian target of rapamycin (mTOR) regulates multiple pathophysiological processes, such as cell development, angiogenesis, autophagy, as well as innate-adaptive immune responses. Numerous studies have demonstrated that mTOR signaling plays an important role in the process of atherosclerosis (AS) itself or AS-related diseases. The activation of mTOR signaling contributes to the endothelium dysfunction and the formation of foam cells via enhancing the process from monocyte to macrophage in the initial stage of atherosclerosis. The activation of mTOR signaling not only promotes the formation of the fatty streak (more foam cells), and migration and proliferation of vascular smooth muscle cells in the early lesion of AS, but also facilitates the formation of vulnerable plaque and replication of vascular smooth muscle cells in the late lesion of AS. Moreover, it has been found the role of the upstream and downstream components of mTOR signaling pathway in the formation of AS. Thus, the mTOR inhibitors may be a promising target for the prevention and treatment of AS.
Keywords: Mammalian target of rapamycin, atherosclerosis, mTOR signaling, foam cell, macrophage, vascular smooth muscle cells.
Current Molecular Medicine
Title:Role of Mammalian Target of Rapamycin in Atherosclerosis
Volume: 18 Issue: 4
Author(s): Z. Cai*, Y. He and Y. Chen
Affiliation:
- Department of Neurology, Chongqing General Hospital, University of Chinese Academy of Sciences, 400013, Chongqing,China
Keywords: Mammalian target of rapamycin, atherosclerosis, mTOR signaling, foam cell, macrophage, vascular smooth muscle cells.
Abstract: The mammalian target of rapamycin (mTOR) regulates multiple pathophysiological processes, such as cell development, angiogenesis, autophagy, as well as innate-adaptive immune responses. Numerous studies have demonstrated that mTOR signaling plays an important role in the process of atherosclerosis (AS) itself or AS-related diseases. The activation of mTOR signaling contributes to the endothelium dysfunction and the formation of foam cells via enhancing the process from monocyte to macrophage in the initial stage of atherosclerosis. The activation of mTOR signaling not only promotes the formation of the fatty streak (more foam cells), and migration and proliferation of vascular smooth muscle cells in the early lesion of AS, but also facilitates the formation of vulnerable plaque and replication of vascular smooth muscle cells in the late lesion of AS. Moreover, it has been found the role of the upstream and downstream components of mTOR signaling pathway in the formation of AS. Thus, the mTOR inhibitors may be a promising target for the prevention and treatment of AS.
Export Options
About this article
Cite this article as:
Cai Z. *, He Y. and Chen Y. , Role of Mammalian Target of Rapamycin in Atherosclerosis, Current Molecular Medicine 2018; 18 (4) . https://dx.doi.org/10.2174/1566524018666180926163917
DOI https://dx.doi.org/10.2174/1566524018666180926163917 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs)
Current Vascular Pharmacology Safety and Efficacy of Novel Oral Anticoagulants: A Comparison to Vitamin K Antagonists
Cardiovascular & Hematological Agents in Medicinal Chemistry Atrial Conduction Disorders
Current Cardiology Reviews Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews The Role of Colchicine in Pericardial Syndromes
Current Pharmaceutical Design Obesity and Pregnancy
Current Women`s Health Reviews Natural Products to Anti-trypanosomal Drugs: An Overview of New Drug Prototypes for American Trypanosomiasis
Cardiovascular & Hematological Agents in Medicinal Chemistry Assessing Myocardial Metabolism with Hybrid PET Imaging: Instrumentation, Concepts, and Workflows
Current Pharmaceutical Design Restoration of Cardiomyocyte Function in Streptozotocin-Induced Diabetic Rats after Treatment with Vanadate in a Tea Decoction
Current Pharmaceutical Biotechnology Clinical Assessment of Central Blood Pressure
Current Hypertension Reviews Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery
Current Topics in Medicinal Chemistry Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery From CHD Susceptibility Genes to New Therapeutics
Current Pharmacogenomics New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews The Fallacy of the Longevity Elixir: Negligible Senescence May be Achieved, but Not by Using Something Physical
Current Aging Science Clinical Applications of Nanotechnology in Atherosclerotic Diseases
Current Nanoscience Effect of Fasting Ramadan in Diabetes Control Status - Application of Extensive Diabetes Education, Serum Creatinine with HbA1c Statistical ANOVA and Regression Models to Prevent Hypoglycemia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery